Arcus Biosciences (RCUS) Operating Expenses (2017 - 2026)

Arcus Biosciences' Operating Expenses history runs 10 years deep, the most recent figure standing at $151.0 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 0.67% year-over-year to $151.0 million in Q1 2026; TTM through Mar 2026 was $634.0 million, a 9.88% increase from a year earlier, with the FY2025 full-year figure at $633.0 million, up 7.65% from the prior year.
• Operating Expenses advanced to $151.0 million in Q1 2026 per RCUS's latest filing, from $147.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $168.0 million in Q2 2025 and bottomed at $85.0 million in Q1 2022.
• The 5-year median for Operating Expenses is $129.0 million (2024), against an average of $130.6 million.
• Across the five-year window, Operating Expenses surged 46.74% in 2022 and decreased 6.83% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $108.0 million in 2022, then advanced by 12.96% to $122.0 million in 2023, then grew by 5.74% to $129.0 million in 2024, then increased by 13.95% to $147.0 million in 2025, then advanced by 2.72% to $151.0 million in 2026.
• Per Business Quant, the three latest RCUS Operating Expenses figures stand at $151.0 million (Q1 2026), $147.0 million (Q4 2025), and $168.0 million (Q3 2025).